AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices
DANIEL CARPENTER: Thanks for having me.
SULLIVAN: Dan, before we dissect policy, let’s rewind the tape to your origin story. Can you take us to the moment that you first became fascinated with regulators rather than, say, politicians? Was there a spark that pulled you toward the FDA story?
CARPENTER: At one point during graduate school, I was studying a combination of American politics and political theory, and I did a summer interning at the Department of Housing and Urban Development. And I began to think, why don’t people study these administrators more and the rules they make, the, you know, inefficiencies, the efficiencies? Really more from, kind of, a descriptive standpoint, less from a normative standpoint. And I was reading a lot that summer about the